Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent.

di Pietro A, Koster R, Boersma-van Eck W, Dam WA, Mulder NH, Gietema JA, de Vries EG, de Jong S.

Cell Cycle. 2012 Dec 15;11(24):4552-62. doi: 10.4161/cc.22803. Epub 2012 Nov 19.

2.

Disparities in survival of stomach cancer among different socioeconomic groups in North-East Netherlands.

Siemerink EJ, Hospers GA, Mulder NH, Siesling S, van der Aa MA.

Cancer Epidemiol. 2011 Oct;35(5):413-6. doi: 10.1016/j.canep.2011.02.015. Epub 2011 Apr 5.

PMID:
21470931
3.

VEGF-SPECT with ¹¹¹In-bevacizumab in stage III/IV melanoma patients.

Nagengast WB, Hooge MN, van Straten EM, Kruijff S, Brouwers AH, den Dunnen WF, de Jong JR, Hollema H, Dierckx RA, Mulder NH, de Vries EG, Hoekstra HJ, Hospers GA.

Eur J Cancer. 2011 Jul;47(10):1595-602. doi: 10.1016/j.ejca.2011.02.009. Epub 2011 Mar 21.

PMID:
21429739
4.

Retrospective denial as a coping method.

Siemerink EJ, Jaspers JP, Plukker JT, Mulder NH, Hospers GA.

J Clin Psychol Med Settings. 2011 Mar;18(1):65-9. doi: 10.1007/s10880-011-9223-x.

5.

Survival of non-Western first generations immigrants with stomach cancer in North East Netherlands.

Siemerink EJ, van der Aa MA, Siesling S, Hospers GA, Mulder NH.

Br J Cancer. 2011 Mar 29;104(7):1193-5. doi: 10.1038/bjc.2011.64. Epub 2011 Feb 22.

6.

FDG-PET probe-guided surgery for recurrent retroperitoneal testicular tumor recurrences.

de Jong JS, van Ginkel RJ, Slart RH, Lemstra CL, Paans AM, Mulder NH, Hoekstra HJ.

Eur J Surg Oncol. 2010 Nov;36(11):1092-5. doi: 10.1016/j.ejso.2010.08.129. Epub 2010 Sep 15.

PMID:
20828977
7.

Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer.

Siemerink EJ, Drenth AF, Mulder NH, Plukker JT, Hospers GA.

Gastric Cancer. 2010 Jun;13(2):95-100. doi: 10.1007/s10120-010-0545-4. Epub 2010 Jul 3.

PMID:
20602196
8.

Effect of hospital characteristics on outcome of patients with gastric cancer: a population based study in North-East Netherlands.

Siemerink EJ, Schaapveld M, Plukker JT, Mulder NH, Hospers GA.

Eur J Surg Oncol. 2010 May;36(5):449-55. doi: 10.1016/j.ejso.2010.03.011. Epub 2010 Apr 15.

PMID:
20399068
9.

A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report.

Oosting SF, Peters FT, Hospers GA, Mulder NH.

J Med Case Rep. 2010 Jan 15;4:10. doi: 10.1186/1752-1947-4-10.

10.

Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen.

Hospers GA, Meijer C, Dam WA, Roossink F, Mulder NH.

Vaccine. 2009 Dec 11;28(2):386-91. doi: 10.1016/j.vaccine.2009.10.036. Epub 2009 Oct 28.

PMID:
19878752
11.

Skin capillary permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product.

de Leeuw K, Kusumanto Y, Smit AJ, Oomen P, van der Hoeven JH, Mulder NH, Hospers GA.

Diabet Med. 2008 Oct;25(10):1241-4. doi: 10.1111/j.1464-5491.2008.02557.x.

PMID:
19046206
12.

Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients.

Nieboer P, de Vries EG, Mulder NH, Rodenhuis S, Bontenbal M, van der Wall E, van Hoesel QG, Smit WM, Hupperets P, Voest EE, Nooij MA, Boezen HM, van der Graaf WT.

Bone Marrow Transplant. 2008 Oct;42(7):475-81. doi: 10.1038/bmt.2008.195. Epub 2008 Jul 14.

PMID:
18622420
13.

18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.

Siemerink EJ, Mulder NH, Brouwers AH, Hospers GA.

Oncologist. 2008 Jun;13(6):734-5; author reply 736-7. doi: 10.1634/theoncologist.2008-0063. No abstract available.

14.

Effect of CDT6 on factors of angiogenic balance in tumour cell lines.

Bouïs DR, Dam WA, Meijer C, Mulder NH, Hospers GA.

Anticancer Res. 2007 Jul-Aug;27(4B):2325-9.

15.

Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.

Hospers GA, Punt CJ, Tesselaar ME, Cats A, Havenga K, Leer JW, Marijnen CA, Jansen EP, Van Krieken HH, Wiggers T, Van de Velde CJ, Mulder NH.

Ann Surg Oncol. 2007 Oct;14(10):2773-9. Epub 2007 Jul 26.

16.

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN.

J Nucl Med. 2007 Aug;48(8):1313-9. Epub 2007 Jul 13.

17.

Improvement of in vivo transfer of plasmid DNA in muscle: comparison of electroporation versus ultrasound.

Kusumanto YH, Mulder NH, Dam WA, Losen M, De Baets MH, Meijer C, Hospers GA.

Drug Deliv. 2007 Jul;14(5):273-7. Erratum in: Drug Deliv. 2007 Oct;14(7):481. Losen, Mario H [corrected to Losen, Mario]; De Baets, Marc H [added].

PMID:
17613014
18.
19.

Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.

van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.

J Clin Oncol. 2006 Nov 1;24(31):4998-5004.

PMID:
17075118
20.

Outcome of palliative care regimens in patients with advanced oesophageal cancer detected during explorative surgery.

Pultrum BB, van Westreenen HL, Mulder NH, van Dullemen HM, Plukker JT.

Anticancer Res. 2006 May-Jun;26(3B):2289-93.

21.

Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.

Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM, Sluiter WJ, Tio RA, Quax PH, Gans RO, Dullaart RP, Hospers GA.

Hum Gene Ther. 2006 Jun;17(6):683-91.

PMID:
16776576
22.

Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response.

Kusumanto YH, Tio RA, Loef BG, Sluiter WJ, Mulder NH, Hospers GA.

Acute Card Care. 2006;8(1):41-5.

PMID:
16720427
23.

Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.

Hospers GA, Schaapveld M, Nortier JW, Wils J, van Bochove A, de Jong RS, Creemers GJ, Erjavec Z, de Gooyer DJ, Slee PH, Gerrits CJ, Smit JM, Mulder NH.

Ann Oncol. 2006 Mar;17(3):443-9.

24.

18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers.

Buursma AR, Rutgers V, Hospers GA, Mulder NH, Vaalburg W, de Vries EF.

Nucl Med Commun. 2006 Jan;27(1):25-30.

PMID:
16340720
25.

A review on pro- and anti-angiogenic factors as targets of clinical intervention.

Bouïs D, Kusumanto Y, Meijer C, Mulder NH, Hospers GA.

Pharmacol Res. 2006 Feb;53(2):89-103. Review.

PMID:
16321545
26.

Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.

Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WT, TenVergert EM, van Tinteren H, de Vries EG.

J Clin Oncol. 2005 Nov 20;23(33):8296-304. Epub 2005 Oct 11.

PMID:
16219926
27.

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT.

J Clin Oncol. 2005 Aug 20;23(24):5635-43.

PMID:
16110022
28.

Influence of p53 status on the HSV-Tk/GCV-induced bystander effect in a panel of human ovarian carcinoma cell lines.

van Dillen IJ, Mulder NH, Sluiter WJ, Meijer C, de Jong S, Loncarek J, Mesnil M, de Vries EF, Vaalburg W, Hospers GA.

Oncol Res. 2005;15(3):151-9.

PMID:
16050136
29.

Antagonism of HSV-tk transfection and ganciclovir treatment on chemotherapeutic drug sensitivity.

Van Dillen IJ, Mulder NH, Meijer C, Dam WA, Kamstra E, De Vries L, Meersma GJ, Van der Zee AG, De Vries EF, Vaalburg W, Hospers GA.

J Chemother. 2005 Jun;17(3):289-96.

PMID:
16038523
30.

[New oncolytic agents and immunomodulators and their application].

Mulder NH.

Ned Tijdschr Geneeskd. 2005 Jun 25;149(26):1438-40. Dutch.

PMID:
16010953
31.

Relevance of high-dose chemotherapy in solid tumours.

Nieboer P, de Vries EG, Mulder NH, van der Graaf WT.

Cancer Treat Rev. 2005 May;31(3):210-25. Epub 2005 Mar 19. Review.

PMID:
15944050
32.

[18F]FHPG positron emission tomography for detection of herpes simplex virus (HSV) in experimental HSV encephalitis.

Buursma AR, de Vries EF, Garssen J, Kegler D, van Waarde A, Schirm J, Hospers GA, Mulder NH, Vaalburg W, Klein HC.

J Virol. 2005 Jun;79(12):7721-7.

33.

Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy.

Elias M, van Zanten J, Hospers GA, Setroikromo A, de Jong MA, de Leij LF, Mulder NH.

J Clin Apher. 2005 Dec;20(4):197-207.

PMID:
15892082
34.

Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study.

Reerink O, Mulder NH, Verschueren RC, Wiggers T, Szabo BG, Hospers GA.

Anticancer Res. 2005 Jan-Feb;25(1B):629-33.

35.

Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ganciclovir-induced bystander effect in a human small cell lung cancer cell line model.

Van Dillen IJ, Mulder NH, Sluiter WJ, Meijer C, De Jong S, Loncarek J, Mesnil M, De Vries EF, Vaalburg W, Hospers GA.

Anticancer Res. 2005 Jan-Feb;25(1A):255-61.

36.

Circulating vascular endothelial growth factor during the normal menstrual cycle.

Kusumanto YH, Hospers GA, Sluiter WJ, Dam WA, Meijer C, Mulder NH.

Anticancer Res. 2004 Nov-Dec;24(6):4237-41.

37.

Monitoring HSVtk suicide gene therapy: the role of [(18)F]FHPG membrane transport.

Buursma AR, van Dillen IJ, van Waarde A, Vaalburg W, Hospers GA, Mulder NH, de Vries EF.

Br J Cancer. 2004 Dec 13;91(12):2079-85.

38.

Developments in treatment of primary irresectable rectal cancer.

Reerink O, Mulder NH, Szabo BG, Sluiter WJ, Wiggers T, Bongaerts AH, Hospers GA.

Colorectal Dis. 2004 Nov;6(6):406-17. Review.

PMID:
15521928
39.

Treatment of locally recurrent rectal cancer, results and prognostic factors.

Reerink O, Mulder NH, Botke G, Sluiter WJ, Szabó BG, Plukker JT, Verschueren RC, Hospers GA.

Eur J Surg Oncol. 2004 Nov;30(9):954-8.

PMID:
15498640
40.

Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.

Heeren PA, Kloppenberg FW, Hollema H, Mulder NH, Nap RE, Plukker JT.

Anticancer Res. 2004 Jul-Aug;24(4):2579-83.

41.

The happy destiny of frozen haematopoietic stem cells: from immature stem cells to mature applications.

de Vries EG, Vellenga E, Kluin-Nelemans JC, Mulder NH.

Eur J Cancer. 2004 Sep;40(13):1987-92. Review.

PMID:
15315808
42.

5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients.

Reerink O, Mulder NH, Szabo BG, Hospers GA.

Anticancer Res. 2004 May-Jun;24(3b):1969-71.

43.
44.

Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy.

Reerink O, Karrenbeld A, Plukker JT, Verschueren RC, Szabó BG, Sluiter WJ, Hospers GA, Mulder NH.

Anticancer Res. 2004 Mar-Apr;24(2C):1217-21.

45.

Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis.

Nieboer P, de Vries EG, Vellenga E, van der Graaf WT, Mulder NH, Sluiter WJ, de Wolf JT.

Eur J Cancer. 2004 May;40(8):1199-207.

PMID:
15110884
46.

combination of vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) to improve angiogenic gene therapy.

Bouïs D, Boelens MC, Peters E, Koolwijk P, Stob G, Kema IP, Klinkenberg M, Mulder NH, Hospers GA.

Angiogenesis. 2003;6(3):185-92.

PMID:
15041794
47.

Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study.

Groen HJ, van der Leest AH, Fokkema E, Timmer PR, Nossent GD, Smit WJ, Nabers J, Hoekstra HJ, Hermans J, Otter R, van Putten JW, de Vries EG, Mulder NH.

Ann Oncol. 2004 Mar;15(3):427-32.

48.

Modulation of death receptor pathways in oncology.

de Vries EG, Timmer T, Mulder NH, van Geelen CM, van der Graaf WT, Spierings DC, de Hooge MN, Gietema JA, de Jong S.

Drugs Today (Barc). 2003;39 Suppl C:95-109. Review.

PMID:
14988748
49.

Evaluation of [18F]FHPG as PET tracer for HSVtk gene expression.

de Vries EF, van Dillen IJ, van Waarde A, Willemsen AT, Vaalburg W, Mulder NH, Hospers GA.

Nucl Med Biol. 2003 Aug;30(6):651-60.

PMID:
12900291
50.

Screening for infectious foci in breast cancer patients prior to high-dose chemotherapy and stem cell transplantation.

Nieboer P, Roodenburg JL, van der Laan BF, de Vries EG, Mulder NH, van der Graaf WT.

Anticancer Res. 2003 Mar-Apr;23(2C):1779-83.

PMID:
12820458

Supplemental Content

Loading ...
Support Center